HK1147695A1 - Pharmaceutical solid state forms - Google Patents

Pharmaceutical solid state forms

Info

Publication number
HK1147695A1
HK1147695A1 HK11101901.3A HK11101901A HK1147695A1 HK 1147695 A1 HK1147695 A1 HK 1147695A1 HK 11101901 A HK11101901 A HK 11101901A HK 1147695 A1 HK1147695 A1 HK 1147695A1
Authority
HK
Hong Kong
Prior art keywords
solid state
3alpha
5alpha
17alpha
17beta
Prior art date
Application number
HK11101901.3A
Other languages
English (en)
Inventor
Steven K White
Dwight Stickney
Erin Olson
Keith R Lorimer
Brenton S Wolfe
Original Assignee
Harbor Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harbor Therapeutics Inc filed Critical Harbor Therapeutics Inc
Publication of HK1147695A1 publication Critical patent/HK1147695A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0033—Androstane derivatives substituted in position 17 alfa and 17 beta
    • C07J1/004—Androstane derivatives substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being an unsaturated hydrocarbon group
    • C07J1/0048—Alkynyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
HK11101901.3A 2008-02-05 2011-02-25 Pharmaceutical solid state forms HK1147695A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2647208P 2008-02-05 2008-02-05
US9369408P 2008-09-02 2008-09-02
PCT/US2009/033280 WO2009100258A1 (en) 2008-02-05 2009-02-05 Pharmaceutical solid state forms

Publications (1)

Publication Number Publication Date
HK1147695A1 true HK1147695A1 (en) 2011-08-19

Family

ID=40952461

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11101901.3A HK1147695A1 (en) 2008-02-05 2011-02-25 Pharmaceutical solid state forms

Country Status (11)

Country Link
US (4) US8518922B2 (de)
EP (1) EP2249838A4 (de)
JP (1) JP2011511011A (de)
KR (1) KR20100113602A (de)
CN (2) CN103467554A (de)
AU (1) AU2009212314C1 (de)
CA (1) CA2712005C (de)
EA (1) EA018974B9 (de)
HK (1) HK1147695A1 (de)
IL (1) IL207378A0 (de)
WO (1) WO2009100258A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2273994T3 (en) * 2008-04-03 2016-02-01 Neurmedix Inc PHARMACEUTICAL FORMS OF A MEDICINE
EP2506855A4 (de) * 2009-11-30 2014-07-30 Harbor Biosciences Inc Antikarzinomverbindungen und screeningverfahren
CA2787027A1 (en) 2010-01-13 2011-07-21 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Detection of gastrointestinal disorders
JP5808349B2 (ja) 2010-03-01 2015-11-10 カリス ライフ サイエンシズ スウィッツァーランド ホールディングスゲーエムベーハー セラノーシスのためのバイオマーカー
JP2013526852A (ja) 2010-04-06 2013-06-27 カリス ライフ サイエンシズ ルクセンブルク ホールディングス 疾患に対する循環バイオマーカー
AU2011343599A1 (en) * 2010-12-17 2013-05-09 Harbor Biosciences, Inc. Steroid tetrol solid state forms
CN104173353B (zh) * 2013-05-22 2018-08-21 中国医药工业研究总院 不含表面活性剂的固体制剂及其制备方法
JP6963896B2 (ja) * 2013-11-12 2021-11-10 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated Ｃｆｔｒ媒介性疾患の処置のための医薬組成物を調製する方法
CN105434444B (zh) * 2014-09-29 2021-02-05 上海奥奇医药科技有限公司 一种A-失碳-5α雄甾烷化合物的口服制剂
MX2017005163A (es) 2014-11-17 2018-01-18 Arno Therapeutics Inc Composiciones de liberación prolongada de onapristona y métodos.
BR112018005999A2 (pt) 2015-09-25 2019-01-08 Context Biopharma Inc métodos para a produção de intermediários de onapristona
CN108883067B (zh) 2015-12-15 2021-03-09 康特斯生物制药公司 非晶奥那司酮组合物及其制备方法
US20180148471A1 (en) 2016-11-30 2018-05-31 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection
CN110446705B (zh) * 2017-03-30 2023-04-14 默克专利股份公司 (s)-[2-氯-4-氟-5-(7-吗啉-4-基喹唑啉-4-基)苯基]-(6-甲氧基-哒嗪-3-基)甲醇的固体形式
RU2668526C1 (ru) * 2017-08-18 2018-10-01 Федеральное государственное бюджетное учреждение "Информационно-методический центр по экспертизе, учету и анализу обращения средств медицинского применения" Федеральной службы по надзору в сфере здравоохранения Способ идентификации и последующего количественного определения основных компонентов в инъекционных лекарственных средствах
WO2020113237A1 (en) 2018-11-30 2020-06-04 Caris Mpi, Inc. Next-generation molecular profiling
CN111773388B (zh) * 2019-04-04 2023-07-18 上海奥奇医药科技有限公司 A-失碳-5α雄甾烷化合物类药物与抗癌药物的联合应用
WO2021112918A1 (en) 2019-12-02 2021-06-10 Caris Mpi, Inc. Pan-cancer platinum response predictor

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE681869C (de) * 1935-11-22 1939-10-03 Schering Ag Verfahren zur Darstellung von tertiaeren Alkoholen der Cyclopentanopolyhydrophenanthrenreihe
CH202847A (de) 1937-06-26 1939-02-15 Chem Ind Basel Verfahren zur Darstellung von Acetylen-Derivaten der Cyclopentanopolyhydrophenanthren-Reihe.
JP3179495B2 (ja) 1992-08-28 2001-06-25 ボーン ケア インターナショナル インコーポレイテッド １α，２４（Ｓ）−ジヒドロキシビタミンＤ▲下２▼の調製及び使用方法
US5567830A (en) * 1994-02-14 1996-10-22 Cocensys, Inc. Process for synthesis of acetylenic carbinols
PL189256B1 (pl) 1996-03-29 2005-07-29 Duphar Int Res Związki piperazyny i piperydyny, sposób ich wytwarzania, kompozycja farmaceutyczna zawierająca te związki, zastosowanie tych związków do wytwarzania leków
ZA986614B (en) 1997-07-25 1999-01-27 Gilead Sciences Nucleotide analog composition
US7045513B1 (en) 1999-03-18 2006-05-16 Genelabs Technologies, Inc. DHEA composition and method
CA2670236C (en) 1999-09-30 2012-06-05 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatment of androgen receptor driven conditions
US6777399B2 (en) * 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
WO2002047693A2 (en) 2000-12-14 2002-06-20 Ortho-Mcneil Pharmaceutical, Inc. Steroid hormone products comprising a stabilizing agent in non-crystalline form
AR034206A1 (es) 2001-02-16 2004-02-04 Solvay Pharm Bv Un procedimiento para la preparacion de mesilatos de derivados de piperazina y dichos mesilatos
DE10314610A1 (de) 2003-04-01 2004-11-04 Aventis Pharma Deutschland Gmbh Neues Diphenylazetidinon mit verbesserten physiologischen Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindungen enthaltende Arzneimittel und dessen Verwendung
US7540016B2 (en) * 2004-07-21 2009-05-26 Beachhead Solutions, Inc. System and method for lost data destruction of electronic data stored on a portable electronic device which communicates with servers that are inside of and outside of a firewall
US7964604B2 (en) 2005-02-18 2011-06-21 Solvay Pharmaceuticals B.V. Bifeprunox mesylate maintenance dose compositions and methods for using the same
TW200730505A (en) * 2005-12-07 2007-08-16 Merck & Co Inc Polymorphs of an androgen receptor modulator
TWI305979B (en) * 2006-03-24 2009-02-01 Hon Hai Prec Ind Co Ltd Wireless transceiving system
EP2486924B1 (de) * 2006-04-22 2018-12-26 Neurmedix, Inc. Wirkstoffe und deren Anwendungen
DE102007054497B3 (de) 2007-11-13 2009-07-23 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung

Also Published As

Publication number Publication date
US20090291932A1 (en) 2009-11-26
CA2712005A1 (en) 2009-08-13
US9314471B2 (en) 2016-04-19
CN101939009A (zh) 2011-01-05
AU2009212314A1 (en) 2009-08-13
CN103467554A (zh) 2013-12-25
AU2009212314B2 (en) 2013-11-21
EP2249838A4 (de) 2012-05-02
US20130345455A1 (en) 2013-12-26
US8518922B2 (en) 2013-08-27
JP2011511011A (ja) 2011-04-07
US20130345184A1 (en) 2013-12-26
US20130338125A1 (en) 2013-12-19
WO2009100258A1 (en) 2009-08-13
EA201070713A1 (ru) 2011-08-30
EP2249838A1 (de) 2010-11-17
CA2712005C (en) 2014-04-15
AU2009212314C1 (en) 2014-05-08
CN101939009B (zh) 2013-07-17
KR20100113602A (ko) 2010-10-21
EA018974B1 (ru) 2013-12-30
IL207378A0 (en) 2010-12-30
EA018974B9 (ru) 2014-04-30

Similar Documents

Publication Publication Date Title
HK1147695A1 (en) Pharmaceutical solid state forms
PH12019501792A1 (en) Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
PH12013502369A1 (en) Diazacarbazoles and methods of use
MX2020012825A (es) Compuestos multiciclicos y metodos de uso de los mismos.
UA102251C2 (ru) Производные аминодигидротиазина как ингибиторы васе для лечения болезни альцгеймера
TN2010000040A1 (en) 2-3-7-substituted imidazo - [1-2b] pyridazines for treatment of alk 4 or alk 5 mediated diseases
HK1169321A1 (en) Diarylhydantoin compounds as androgen receptor antagonists for treatment of cancer
TN2012000231A1 (en) Quinoline amide m1 receptor positive allosteric modulators
TN2012000171A1 (en) Synthetic methods for spiro-oxindole compounds
MX2012006822A (es) 1,7-diazacarbazoles y metodos de uso.
MX2009000531A (es) Derivados heterociclicos fusionados y metodos de uso.
MX339709B (es) Antagonistas de wnt y metodos de tratamiento y analisis.
SG10201811480WA (en) Therapeutic compounds and compositions
MX2009006466A (es) Metodos de tratamiento de cancer con inhibidores del receptor del factor 1 de crecimiento similar a la insulina.
EP2582676A4 (de) Positive allosterische tetrahydrochinolin-amid-m1-rezeptormodulatoren
MX367623B (es) 6-amino-nicotinamidas sustituidas como moduladores de kcnq2/3.
WO2014194245A3 (en) Cdk8 inhibitors and uses thereof
MY160075A (en) Pyranyl aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
MX2010010799A (es) Metodo de diagnostico, prevencion y tratamiento de las enfermedades de la masa osea.
MY164998A (en) Isoquinolinone derivatives as nk3 antagonists
IL206738A0 (en) Novel quinazoline-2,4-dione derivative, and medical compositions for the prophylaxis and treatment of cranial nerve disease containing the same
EP2073635A4 (de) Makrozyklische spiropiperidin-beta-sekretase-hemmer zur behandlung von morbus alzheimer
IL195969A0 (en) Azaindole derivatives with a combination of partial nicotinic acetylcholine receptor agonism and dopamine reuptake inhibition
NO20064185L (no) Pyrazolin derivater nyttige for bahandling av kreft
MX2010013608A (es) Pirroles sustituidos y metodos de uso.

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20170205